Lukas Herold

Dr. Lukas Herold

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDirk Von Lewinski
Dirk Von Lewinski
LHLukas Herold
Lukas Herold
EBEva Bachl
Eva Bachl
HBHeiko Bugger
Heiko Bugger
TGTheresa Glantschnig
Theresa Glantschnig
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes in subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria with a real-world cohort of CS patients. Methods and Results: ECLS-SHOCK eligibility criteria were applied to a prospective single-center CS registry (the PREPARE CS registry) consisting of 557 patients who were consecutively admitted to the catheterization laboratory (cath lab) of the Medical University of Graz, Austria, due to CS (SCAI C-E). Overall use of mechanical circulatory support (MCS) in this cohort was 19%. Sixty-nine percent of the entire cohort had MI-related CS, 38% of whom would have met ECLS-SHOCK eligibility criteria, thus representing only 27% of the PREPARE CS registry. Exclusion from the ECLS-SHOCK trial was based on patients with initial lactate values below 3 mmol/L (n = 168; 43.6%), aged over 80 years (n = 65; 16.9%), and with a duration of cardiopulmonary resuscitation (CPR) exceeding 45 min (n = 22; 5.7%). The 30-day mortality of patients of the PREPARE CS registry who met the ECLS-SHOCK eligibility criteria was 57.0%, compared to 48.4% of patients in the ECLS-SHOCK trial. The patients’ baseline characteristics, however, differed considerably with respect to type of infarction, age, and gender. Conclusions: In a real-world cohort of patients with MI-related CS, only 38% of patients met the eligibility criteria of the ECLS-SHOCK trial. Thus, the impact of the use of VA-ECMO on outcome parameters in MI-related CS, as observed in the ECLS-SHOCK trial, may differ in a more heterogeneous real-world CS population of the PREPARE CS registry.

Verified
Journal Article
Open access
PDF file
DPDan Mihai Prunea
Dan Mihai Prunea
EBEva Bachl
Eva Bachl
LHLukas Herold
Lukas Herold
SSSadeek Sidney Kanoun Schnur
Sadeek Sidney Kanoun Schnur
SPSascha Pätzold
Sascha Pätzold
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
(1) Background: Mechanical circulatory support (MCS) in myocardial infarction-associated cardiogenic shock is subject to debate. This analysis aims to elucidate the impact of MCS’s timing on patient outcomes, based on data from the PREPARE CS registry. (2) Methods: The PREPARE CS prospective registry includes patients who experienced cardiogenic shock (SCAI classes C–E) and were subsequently referred for cardiac catheterization. Our present analysis included a subset of this registry, in whom MCS was used and who underwent coronary intervention due to myocardial infarction. Patients were categorized into an Upfront group and a Procedural group, depending on the timing of MCS’s introduction in relation to their PCI. The endpoint was in-hospital mortality. (3) Results: In total, 71 patients were included. MCS was begun prior to PCI in 33 (46%) patients (Upfront), whereas 38 (54%) received MCS during or after the initiation of PCI (Procedural). The groups’ baseline characteristics and hemodynamic parameters were comparable. The Upfront group had a higher utilization of the Impella® device compared to extracorporeal membrane oxygenation (67% vs. 33%), while the Procedural group exhibited a balanced use of both (50% vs. 50%). Most patients suffered from multi-vessel disease in both groups (82% vs. 84%, respectively; p = 0.99), and most patients required a complex PCI procedure; the latter was more prevalent in the Upfront group (94% vs. 71%, respectively; p = 0.02). Their rates of complete revascularization were comparable (52% vs. 34%, respectively; p = 0.16). Procedural CPR was significantly more frequent in the Procedural group (45% vs. 79%, p < 0.05); however, in-hospital mortality was similar (61% vs. 79%, respectively; p = 0.12). (4) Conclusions: The upfront implantation of MCS in myocardial infarction-associated CS did not provide an in-hospital survival benefit.

12 October 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
RPRaffaela Miriam Planka
Raffaela Miriam Planka
LHLukas Herold
Lukas Herold
TGTheresa Glantschnig
Theresa Glantschnig
GSGudrun Sommer
Gudrun Sommer
JPJonathan Pavek
Jonathan Pavek
DLDirk Von Lewinski
Dirk Von Lewinski
Background: The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline‐recommended therapy in patients with ST‐elevation myocardial infarction (STEMI)‐related cardiogenic shock (CS), finding a lower all‐cause mortality at 180 days in the intervention group. Methods: DanGer Shock eligibility criteria were applied to the prospective single‐center PREPARE CardShock registry, which consecutively enrolled 721 patients between April 2019 and August 2024 with advanced CS—classified as stages C to E according to the SCAI shock classification—who were on vasoactive medication and underwent cardiac catheterization. Results: Among 721 patients in the registry, 384 (53.3%) had STEMI‐related CS. Of those, 117 (30.5%) met DanGer Shock trial eligibility criteria, accounting for 16.2% of the registry cohort. Median age of the eligible patients was 68 years (interquartile range [IQR]: 58–78), and 62.4% were male, compared to 68 years (IQR: 60–76) and 79.2% in DanGer Shock. PREPRARE‐CS DanGer Shock eligible patients had a higher median systolic blood pressure (SBP) (92 mmHG [78–107] vs. 83 mmHG, [72–91]) and higher median lactate levels (5.2 mmol/L [3.6–7.6] vs. 4.6 mmol/L [3.3–7.0]) at baseline, and were more frequently resuscitated (56.4% vs. 20.3%). Device use was 42.7% in eligible patients. Renal replacement therapy (RRT) was more frequent among trial participants (34.4% vs. 17.1%). The 180‐day mortality rate among eligible patients was 71.8%, compared to 52.1% in trial participants. Conclusions: Among STEMI‐related CS patients in our cohort, only one‐third met the DanGer Shock eligibility criteria. Consequently, trial outcomes may not be broadly applicable.

11 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
DPDan Mihai Prunea
Dan Mihai Prunea
EBEva Bachl
Eva Bachl
LHLukas Herold
Lukas Herold
SSSadeek Sidney Kanoun Schnur
Sadeek Sidney Kanoun Schnur
SPSascha Pätzold
Sascha Pätzold
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
(1) Background: Mechanical circulatory support (MCS) in myocardial infarction associated cardiogenic shock is subject to debate. This analysis aims to elucidate the impact of MCS timing on patient outcomes, based on data from the PREPARE CS registry.; (2) Methods: PREPARE CS prospective registry included consecutive patients experiencing cardiogenic shock (SCAI Classes C-E) and were referred for cardiac catheterization. Present analysis included a subset, in whom MCS was used and underwent coronary intervention due to myocardial infarction. Patients were categorized into Upfront group versus Procedural group, depending on the timing of MCS introduction in relation to PCI. Endpoint was the in-hospital mortality; (3) Results: In total 71 patients were included. MCS was started prior to PCI in 33 (46%) patients (Upfront), whereas 38 (54%) received MCS during or after PCI initiation (Procedural). Baseline characteristics and hemodynamic parameters were comparable. The Upfront group had a higher utilization of Impella® device compared to extracorporeal membrane oxygenation (67% vs 33%), while the Procedural group exhibited a balanced use (50% vs 50%). Most patients suffered of multi-vessel disease in both groups (82% vs 84%, respectively; p=0.99) and most patients required complex PCI procedure, the latter was more prevalent in the Upfront group (94% vs 71%, respectively; p=0.02). Rates of complete revascularization were comparable (52% vs 34%, respectively; p=0.16). Procedural CPR was significantly more frequent in the Procedural group (45% vs 79%, p<0.05), still in-hospital mortality was similar (61% vs 79%, respectively; p=0.12); (4) Conclusions: Upfront implantation of MCS in myocardial infarction associated CS did not provide in-hospital survival benefit.

31 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LHLukas Herold
Lukas Herold
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
DLDirk Von Lewinski
Dirk Von Lewinski
The treatment and burden of patients with severe ischemic heart disease, whether acute or chronic, remain some of the greatest challenges in cardiology